SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Jul 27, 2017
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: July 27, 2017 · CIK: 0001506251 · Accession: 0001477932-17-003541
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217956
Letter
ctxr_corresp.htmCITIUS PHARMACEUTICALS, INC.
11 Commerce Drive, First Floor
Cranford, New Jersey 07016
July 27, 2017
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-217956
Ladies and Gentlemen:
Reference is made to the Company’s request for acceleration filed as correspondence via EDGAR on July 24, 2017. The Company is no longer requesting that the Registration Statement be declared effective at this time and the Company hereby formally withdraws its request for acceleration as of the effective date.
Should you have any questions regarding the foregoing, please do not hesitate to contact our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Erica Jackson at (919) 781-4000.
Very truly yours,
CITIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm ctxr_corresp.htmCITIUS PHARMACEUTICALS, INC. 11 Commerce Drive, First Floor Cranford, New Jersey 07016 July 27, 2017 Via EDGAR Delivery Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Citius Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-217956 Ladies and Gentlemen: Reference is made to the Company’s request for acceleration filed as correspondence via EDGAR on July 24, 2017. The Company is no longer requesting that the Registration Statement be declared effective at this time and the Company hereby formally withdraws its request for acceleration as of the effective date. Should you have any questions regarding the foregoing, please do not hesitate to contact our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Erica Jackson at (919) 781-4000. Very truly yours, CITIUS PHARMACEUTICALS, INC. By: /s/ Myron Holubiak Myron Holubiak Chief Executive Officer